Publication:
A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

Simple item page
dc.contributor.authorDANE, FAYSAL
dc.contributor.authorsAbali, Huseyin; Yalcin, Suayib; Onal, Huseyin Cem; Dane, Faysal; Oksuzoglu, Berna; Ozdemir, Nuriye; Mertsoylu, Huseyin; Artac, Mehmet; Camci, Celalettin; Karabulut, Bulent; Basal, Fatma Bugdayci; Budakoglu, Burcin; Sendur, Mehmet Ali Nahit; Goktas, Burce; Ozdener, Fatih; Calisgan, Arzu
dc.date.accessioned2022-03-12T16:16:55Z
dc.date.accessioned2026-01-11T11:27:47Z
dc.date.available2022-03-12T16:16:55Z
dc.date.issued2016
dc.identifier.doi10.1200/jco.2016.34.4_suppl.tps182
dc.identifier.eissn1527-7755
dc.identifier.issn0732-183X
dc.identifier.urihttps://hdl.handle.net/11424/225852
dc.identifier.wosWOS:000378109600176
dc.language.isoeng
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.relation.ispartofJOURNAL OF CLINICAL ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleA study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.issue4
oaire.citation.titleJOURNAL OF CLINICAL ONCOLOGY
oaire.citation.volume34

Files

Collections

Araştırma Çıktıları